계명대학교 의학도서관 Repository

Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3β Activation in Cancer Cells

Metadata Downloads
Author(s)
Mi-Yeon JeonSeon Min WooSeung Un SeoSang Hyun KimJu-Ock NamShin KimJong-Wook ParkPeter KubatkaKyoung-jin MinTaeg Kyu Kwon
Keimyung Author(s)
Kim, ShinPark, Jong WookKwon, Taeg Kyu
Department
Dept. of Immunology (면역학)
Journal Title
Cancers
Issued Date
2020
Volume
12
Issue
10
Keyword
dexamethasoneTRAILDR5c-FLIP(L)apoptosisGSK-3β
Abstract
Simple Summary:
Dexamethasone (DEX) is commonly used as immunosuppressive and chemotherapeutic agent. The effects of DEX on cell death is different, depending on cell types and stimuli. Here, we found that DEX inhibited tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death in cancer cells. Upregulation of c-FLIP(L) and downregulation of death receptor 5 (DR5) play a critical role in anti-apoptotic effects of DEX in TRAIL-induced apoptosis. DEX upregulated c-FLIP(L) expression at the transcriptional levels through the GSK-3β signaling pathway. Furthermore, DEX also modulated protein stability of DR5 via the GSK-3β/Cbl axis-mediated ubiquitin–proteasome system. Therefore, DEX-induced GSK3β activation plays a critical role in the modulation of c-FLIP(L) and DR5. This finding suggests that DEX reduced effects of anti-cancer drugs in cancer cells.

Abstract:
Dexamethasone (DEX), a synthetic glucocorticoid, is commonly used as immunosuppressive and chemotherapeutic agent. This study was undertaken to investigate the effects of DEX on the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in cancer cells. We found that upregulation of c-FLIP(L) and downregulation of death receptor 5 (DR5; receptor for TRAIL ligand) contribute to the anti-apoptotic effect of DEX on TRAIL-induced apoptosis. DEX increased c-FLIP(L) expression at the transcriptional levels through the GSK-3β signaling pathway. The pharmacological inhibitor and catalytic mutant of GSK-3β suppressed DEX-induced upregulation of c-FLIP(L) expression. Furthermore, GSK-3β specific inhibitor markedly abolished DEX-mediated reduction of TRAIL-induced apoptosis in human renal cancer cells (Caki-1 and A498), human lung cancer cells (A549), and human breast cancer cells (MDA-MB361). In addition, DEX decreased protein stability of DR5 via GSK-3β-mediated upregulation of Cbl, an E3 ligase of DR5. Knockdown of Cbl by siRNA markedly inhibited DEX-induced DR5 downregulation. Taken together, these results suggest that DEX inhibits TRAIL-mediated apoptosis via GSK-3β-mediated DR5 downregulation and c-FLIP(L) upregulation in cancer cells.
Keimyung Author(s)(Kor)
김신
박종욱
권택규
Publisher
School of Medicine (의과대학)
Citation
Mi-Yeon Jeon et al. (2020). Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3β Activation in Cancer Cells. Cancers, 12(10), 2901. doi: 10.3390/cancers12102901
Type
Article
ISSN
2072-6694
Source
https://www.mdpi.com/2072-6694/12/10/2901
DOI
10.3390/cancers12102901
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43000
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Immunology (면역학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.